Drug Trial Radar · NCT01768559
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
Last checked: Nov 20, 2026Latest source record: Jan 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
894
Actual
Start
Jan 2013
Primary completion
Dec 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 15, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: \- To compare lixisenatide versus insulin glulisine in terms of glycosylated hemoglobin (HbA1c) reduction and body weight change at Week 26 in type 2 diabetic participants not adequately controlled on insulin glargine ± metformin. Secondary Objectives: \- To compare the treatments/regimens on: * The percentage of participants reaching the target of HbA1c \<7% or ≤6.5%, * Body weight, * Self-Monitored Glucose profiles, * Fasting Plasma Glucose (FPG), * Post-prandial plasma glucose (PPG) /glucose excursions during a standardized meal test (subset of participants), * Daily doses of insulins, * Safety and tolerability.
Conditions
- Type 2 Diabetes
Interventions
Lixisenatide (AVE0010)Drug
Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection 30 to 60 minutes before breakfast or dinner.
Insulin glulisine QDDrug
Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before breakfast or dinner. The initial dose was 3-5 units and then individually titrated to obtain the SMPG value \>5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before lunch (if administered at breakfast) or at bedtime (if administered at dinner).
Insulin glulisine TIDDrug
Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before each meal. The initial dose was 3-5 units for each meal and then individually titrated to obtain the SMPG value \>5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before the next meal or at bedtime (for injection at dinner).
Insulin Glargine (Mandatory background drug)Drug
Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection at breakfast or dinner. Doses were adjusted to maintain a fasting self-monitored plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL).
Metformin (Background drug)Drug
Pharmaceutical form: Tablet; Route of administration: Oral administration. If previously taken, Metformin to be continued at stable dose (≥1.5 g/day) throughout the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c From Baseline to Week 26Time frame: Baseline, Week 26
- Change in Body Weight From Baseline to Week 26Time frame: Baseline, Week 26
Locations
199 sites in 18 countries. Site status is shown where the registry gives one.
Investigational Site Number 840043
Sun City, Arizona
Investigational Site Number 840042
Tempe, Arizona
Investigational Site Number 840003
Little Rock, Arkansas
Investigational Site Number 840031
La Mesa, California
Investigational Site Number 840005
Mission Viejo, California
Investigational Site Number 840057
Northridge, California
Investigational Site Number 840035
Santa Ana, California
Investigational Site Number 840002
Temecula, California
Investigational Site Number 840037
Walnut Creek, California
Investigational Site Number 840023
West Hills, California
Investigational Site Number 840041
Denver, Colorado
Investigational Site Number 840012
Miami, Florida
Investigational Site Number 840061
Miami, Florida
Investigational Site Number 840045
Lawrenceville, Georgia
Investigational Site Number 840036
Nampa, Idaho
Investigational Site Number 840024
Chicago, Illinois
Investigational Site Number 840009
Evanston, Illinois
Investigational Site Number 840004
Avon, Indiana
Investigational Site Number 840055
Avon, Indiana
Investigational Site Number 840027
Des Moines, Iowa
Investigational Site Number 840006
Wichita, Kansas
Investigational Site Number 840047
Lexington, Kentucky
Investigational Site Number 840056
Paducah, Kentucky
Investigational Site Number 840022
Marrero, Louisiana
Investigational Site Number 840016
Baltimore, Maryland
Investigational Site Number 840017
Rockville, Maryland
Investigational Site Number 840025
Buckley, Michigan
Investigational Site Number 840048
Dearborn, Michigan
Investigational Site Number 840026
Kalamazoo, Michigan
Investigational Site Number 840049
Las Vegas, Nevada
Investigational Site Number 840029
New Hyde Park, New York
Investigational Site Number 840060
Smithtown, New York
Investigational Site Number 840030
Staten Island, New York
Investigational Site Number 840011
Salisbury, North Carolina
Investigational Site Number 840028
Fargo, North Dakota
Investigational Site Number 840007
Oklahoma City, Oklahoma
Investigational Site Number 840021
Pittsburgh, Pennsylvania
Investigational Site Number 840052
Myrtle Beach, South Carolina
Investigational Site Number 840032
Chattanooga, Tennessee
Investigational Site Number 840033
Nashville, Tennessee
Showing 40 of 199 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.